Albany Molecular Research, Inc.
http://www.amriglobal.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Albany Molecular Research, Inc.
Carlyle Pays Almost $500m For A Fifth Of Piramal Pharma
Private equity group Carlyle has acquired 20% of Piramal's pharma business for close to $500m, with the Indian group expected to use the capital raise to bolster organic and inorganic growth and deleverage the balance sheet.
Carlyle's 20% Stake Gives Piramal Pharma 'War Chest' For Growth
Private equity group Carlyle has acquired 20% of Piramal’s pharma business for close to $500m, with the Indian group expected to use the capital raise to bolster organic and inorganic growth and deleverage the balance sheet.
Biopharma Quarterly Deal-Making Statistics, Q2 2017
Biopharma companies raised $13.4 billion in Q2, mostly through IPOs. Thanks to several billion-dollar deals in Q2, 2017 is shaping up to be a year of CRO consolidations. Big pharma continued divesting assets to smaller biopharma companies.
Deal Watch: Novartis Signs Deals In Migraine & Diabetes
Novartis will invest in the Calgary-based Parvus and collaborate on a Navacim candidate for type 1 diabetes. Japan's Sawai moves into the US market by acquiring Upsher-Smith's generics business, while Denovo acquires a suspended depression candidate from AMRI for its personalized development approach.
Company Information
- Industry
- Contract Research, Toxicology Testing-CRO
- Laboratory Testing Services
- Services
-
Pharmaceuticals
- Generic Drugs
-
Biotechnology
-
Drug Discovery Tools
- ADMET
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Cedarburg Pharmaceuticals, Inc.
- Excelsyn Ltd.
- Hyaluron Inc.
- Gadea Pharmaceutical Group (Crystal Pharma)
- Prime European Therapeuticals S.p.A. (Euticals)